A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma
Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a coh...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Permanyer
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6513ee05ea0740fd8c68b39e553d4c10 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6513ee05ea0740fd8c68b39e553d4c10 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6513ee05ea0740fd8c68b39e553d4c102021-11-09T14:24:21ZA Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma10.24875/RIC.210000700034-83762564-8896https://doaj.org/article/6513ee05ea0740fd8c68b39e553d4c102021-01-01T00:00:00Zhttps://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=377https://doaj.org/toc/0034-8376https://doaj.org/toc/2564-8896Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their association with clinical response (CR), relapse, progression-free survival (PFS), and overall survival (OS). Results: A total of 198 patients were included; of them, 30 (15.2%) had mutations at codon 641, in exon 16 of EZH2. Response was achieved in 151 patients (76.3%), and 43 (21.7%) relapsed or progressed during follow-up. EZH2 mutations were associated with relapse/progression (risk ratio [RR] 1.18; 95% confidence interval [CI] 0.98–1.42; p = 0.031), while a trend for not achieving a complete response was observed (RR: 0.876; 95%CI 0.74–1.038; p = 0.071). Of note, Tyr641His and Tyr641Ser EZH2 mutations were associated with shorter PFS (hazard ratio 3.234; 95% CI 1.149–9.1; p = 0.026). Conclusion: The presence of EZH2 mutations was negatively associated with relapse/progression and showed a trend for lack of complete response. Further studies are needed to define better the prognostic significance of these mutations in Mexican-Mestizo DLBCL patients. Luis F. Oñate-OcañaMayra Ponce-MartínezLucia Taja-ChayebOlga Gutiérrez-HernándezAlejandro Avilés-SalasDavid Cantú-de-LeónAlfonso Dueñas-GonzálezMyrna Candelaria-HernándezPermanyerarticleEZH2 mutations. Diffuse large B-cell lymphoma. Progression-free survival. Overall survival. Cohort study.Internal medicineRC31-1245ENRevista de Investigación Clínica, Vol 73, Iss 6 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
EZH2 mutations. Diffuse large B-cell lymphoma. Progression-free survival. Overall survival. Cohort study. Internal medicine RC31-1245 |
| spellingShingle |
EZH2 mutations. Diffuse large B-cell lymphoma. Progression-free survival. Overall survival. Cohort study. Internal medicine RC31-1245 Luis F. Oñate-Ocaña Mayra Ponce-Martínez Lucia Taja-Chayeb Olga Gutiérrez-Hernández Alejandro Avilés-Salas David Cantú-de-León Alfonso Dueñas-González Myrna Candelaria-Hernández A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| description |
Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. Methods: In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their association with clinical response (CR), relapse, progression-free survival (PFS), and overall survival (OS). Results: A total of 198 patients were included; of them, 30 (15.2%) had mutations at codon 641, in exon 16 of EZH2. Response was achieved in 151 patients (76.3%), and 43 (21.7%) relapsed or progressed during follow-up. EZH2 mutations were associated with relapse/progression (risk ratio [RR] 1.18; 95% confidence interval [CI] 0.98–1.42; p = 0.031), while a trend for not achieving a complete response was observed (RR: 0.876; 95%CI 0.74–1.038; p = 0.071). Of note, Tyr641His and Tyr641Ser EZH2 mutations were associated with shorter PFS (hazard ratio 3.234; 95% CI 1.149–9.1; p = 0.026). Conclusion: The presence of EZH2 mutations was negatively associated with relapse/progression and showed a trend for lack of complete response. Further studies are needed to define better the prognostic significance of these mutations in Mexican-Mestizo DLBCL patients.
|
| format |
article |
| author |
Luis F. Oñate-Ocaña Mayra Ponce-Martínez Lucia Taja-Chayeb Olga Gutiérrez-Hernández Alejandro Avilés-Salas David Cantú-de-León Alfonso Dueñas-González Myrna Candelaria-Hernández |
| author_facet |
Luis F. Oñate-Ocaña Mayra Ponce-Martínez Lucia Taja-Chayeb Olga Gutiérrez-Hernández Alejandro Avilés-Salas David Cantú-de-León Alfonso Dueñas-González Myrna Candelaria-Hernández |
| author_sort |
Luis F. Oñate-Ocaña |
| title |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| title_short |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| title_full |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| title_fullStr |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| title_full_unstemmed |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma |
| title_sort |
cohort study of the prognostic impact of exon-16 ezh2 mutations in a mexican-mestizo population of patients with diffuse large b-cell lymphoma |
| publisher |
Permanyer |
| publishDate |
2021 |
| url |
https://doaj.org/article/6513ee05ea0740fd8c68b39e553d4c10 |
| work_keys_str_mv |
AT luisfonateocana acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT mayraponcemartinez acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT luciatajachayeb acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT olgagutierrezhernandez acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT alejandroavilessalas acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT davidcantudeleon acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT alfonsoduenasgonzalez acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT myrnacandelariahernandez acohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT luisfonateocana cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT mayraponcemartinez cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT luciatajachayeb cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT olgagutierrezhernandez cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT alejandroavilessalas cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT davidcantudeleon cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT alfonsoduenasgonzalez cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma AT myrnacandelariahernandez cohortstudyoftheprognosticimpactofexon16ezh2mutationsinamexicanmestizopopulationofpatientswithdiffuselargebcelllymphoma |
| _version_ |
1718440933535514624 |